With Coherus BioSciences gearing up to exit the biosimilars space altogether – having late last year struck a deal to divest its Udenyca (pegfilgrastim-cbqv) franchise to Intas in a transaction worth more than half a billion dollars – the firm has reported a rise of nearly two-thirds in Udenyca sales in 2024, while at the same time setting out plans for “organizational streamlining” and the loss of around 30% of its 225 employees as it moves ahead to focus on innovative immuno-oncology products.
Coherus Prepares To Wave Goodbye To Udenyca – And 30% Of Its Staff
Final Annual Results Before Transfer Of Pegfilgrastim Franchise
As Coherus prepares to exit the biosimilars space altogether with the divestment of its Udenyca pegfilgrastim franchise, the firm has set out its annual results for 2024 as well as “organizational streamlining” plans.
More from Strategy
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.
• By
With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).
More from Products
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).
• By
Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
With an ambitious goal to file a biosimilar to the world-renowned Botox brand via the US FDA’s 351(k) regulatory pathway, AEON Biopharma has revealed the latest steps in its plan.